Scholar Rock, LLC
http://www.scholarrock.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Scholar Rock, LLC
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Finance Watch: PTC Raises $1bn In Evrysdi Royalty Deal Weeks After Latest Layoffs
Public Company Edition: PTC sold more of its Evrysdi royalties to Royalty Pharma for $1bn. Abivax gained $235.8m in an IPO and concurrent private placement, while Cerevel grossed $450m and Nuvalent and Ultragenyx raised $300m each in follow-on offerings, but Freeline is reviewing strategic options.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: new AstraZeneca ADC lung cancer data seen as underwhelming; William Pao’s aspirations at Pfizer; Scholar Rock’s hopes for SMA asset; Biomarin’s Roctavian launch; and Indian lighthouses deliver gains.
Scholar Rock Looks To Augment Existing Therapies In Spinal Muscular Atrophy
Phase III study under way may lead to filing of drug meant to address muscular component of the rare disease, with existing therapies such as Spinraza targeting neurological aspects.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- ADMET
-
Large Molecule
- Other Names / Subsidiaries
-
- Scholar Rock, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice